Latest Commercial Growth News

First Graphene Limited has reported a landmark quarter with a 156% surge in customer cash receipts and a major industrial-scale production of graphene-enhanced cement, signalling a pivotal step in commercialising graphene across multiple sectors.

Starpharma reports strong progress in strategic collaborations and internal drug development, alongside a 70% surge in Viraleze™ online sales and a solid $18.2 million cash position.

BrainChip Holdings has bolstered its financial position with a A$35 million capital raise and commenced volume production of its AKD1500 neuromorphic AI chip, while deepening its strategic partnership with Parsons’ defence arm.

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Algorae Pharmaceuticals has advanced its AI drug discovery capabilities with the launch of AlgoraeOS v2 and secured key commercial partnerships, including a $3 million debt facility to support expansion in Australia and New Zealand.

Blue Star Helium has achieved its first helium production at the Galactica Project, marking a key milestone as it optimizes plant operations and prepares for commercial ramp-up.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Proteomics International Laboratories has appointed David Morris as CEO and Managing Director, marking a strategic shift towards commercialising its Promarker® diagnostic technology. Morris brings extensive global healthcare leadership experience to lead the company’s next growth phase.

Papyrus Australia has taken a significant step towards commercialisation by signing a $4.2 million supply contract with TBS Mining Solutions for its biodegradable Collar Keeper® products, while advancing its Adelaide R&D facility.

Terragen Holdings has received nearly $1 million in R&D tax incentives, reinforcing its cash position and fueling ongoing development of its innovative agricultural biotech products.

6K Additive has landed a landmark US$27.4 million loan from the US Export-Import Bank, partnering with the Department of War to fund a major expansion in Pennsylvania that will quintuple powder production capacity and create over 50 new jobs.

Titomic Limited has successfully completed a hot fire test on a solid rocket motor thrust chamber made with its Titomic Kinetic Fusion cold spray technology, marking a significant milestone in aerospace additive manufacturing.